Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.200-1.346 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $53.2 billion.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BAYRY. DZ Bank raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday. Finally, UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 0.2%

Shares of BAYRY stock opened at $10.88 on Tuesday. Bayer Aktiengesellschaft has a 1 year low of $6.20 and a 1 year high of $14.85. The firm has a fifty day moving average price of $11.31 and a 200-day moving average price of $10.91. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The company has a market cap of $42.76 billion, a price-to-earnings ratio of -9.80 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, hitting the consensus estimate of $0.18. The company had revenue of $13.24 billion during the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, equities analysts predict that Bayer Aktiengesellschaft will post 1.2 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.